![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CHEMDIV, INC. AND PROQINASE GMBH TO PARTNER IN LEAD DISCOVERY AND PRECLINICAL DEVELOPMENT IN ONCOLOGY
CHEMDIV, INC. AND PROQINASE GMBH TO PARTNER IN LEAD DISCOVERY AND PRECLINICAL DEVELOPMENT IN ONCOLOGY
November 8, 2005
ChemDiv, Inc. of San Diego, CA, and ProQinase GmbH of Freiburg, Germany, announced that they have signed an agreement to establish a partnership in the discovery and preclinical development of new kinase inhibitors. Under the agreement ChemDiv will support design and synthesis of target-focused small molecule libraries, undertake medicinal chemistry for hit to lead and lead optimization, as well as DMPK and certain in vivo experiments. ProQinase will be responsible for in vitro kinase inhibitor screening and profiling on a panel of jointly selected oncology-relevant kinase targets, cellular assays and in vivo experiments.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-07-2005/0004209703&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct